Company Overview of BioMotiv, LLC
BioMotiv, LLC develops medicines for patients. It develops various types of therapeutics, such as small molecules, antibodies, proteins, cell therapies, and nucleotides. The company has a strategic partnership with Takeda Pharmaceutical Company Limited. BioMotiv, LLC was formerly known as BIOU, LLC. The company was founded in 2012 and is based in Cleveland, Ohio.
3605 Warrensville Center Road
Cleveland, OH 44122-2394
Founded in 2012
Key Executives for BioMotiv, LLC
Chief Executive Officer and Member of Board of Managers
Vice President of Business Development
Chairman of Scientific Advisory Board, Chief Scientific Officer and Member of Board of Managers
Compensation as of Fiscal Year 2014.
BioMotiv, LLC Key Developments
BioMotiv, University of California San Francisco and University of Washington Announces Formation of Optikira
Feb 2 15
BioMotiv, the University of California San Francisco and University of Washington are announcing the formation of OptiKira, a platform company that will develop small molecule therapeutics that prevent cell death in pathologies caused by misfolded or unfolded proteins. OptiKira is based on intellectual property exclusively licensed from UCSF and University of Washington. The project was initiated at UCSF and the University of Washington by scientific founders Scott Oakes, MD, Associate Professor of Pathology at UCSF, Feroz Papa, MD, PhD, Associate Professor of Medicine at UCSF, Bradley Backes, PhD, Associate Professor of Medicine at UCSF, and Dustin Maly, PhD, Associate Professor in Chemistry at University of Washington. Dr. Oakes and Dr. Papa are members of the first class of Harrington Scholar-Innovators. Extensive research by the Founders has helped define the biological pathway leading to progressive cell death which characterizes diseases such as retinitis pigmentosa, diabetes, and amyotrophic lateral sclerosis (ALS). They have found that the Unfolded Protein Response (UPR), a mechanism by which the cell deals with functionally abnormal proteins, has an important housekeeping role in cell metabolism. However when overloaded, the 'terminal UPR' results in the accumulation of excessive unfolded proteins and cellular death. The team has synthesized inhibitors of IRE1a to prevent the activation of the terminal UPR, while not disrupting the housekeeping role of the enzyme. They have demonstrated that inhibitors of IRE1a, which they have named kinase-inhibiting RNase attenuators (KIRAs), protect cells from degeneration in preclinical models of retinitis pigmentosa and diabetes.
BioMotiv, LLC Presents at Life Sciences Summit 2014, Oct-29-2014 09:00 AM
Oct 22 14
BioMotiv, LLC Presents at Life Sciences Summit 2014, Oct-29-2014 09:00 AM. Venue: 10 on the Park at Time Warner Center, 60 Columbus Circle, 10th Floor, New York, NY 10019, United States. Speakers: Terry C. Vance, Chief Business Officer.
Takeda Pharmaceutical Company Limited and BioMotiv, LLC Enter into Strategic Partnership
Sep 25 14
Takeda Pharmaceutical Company Limited and BioMotiv, LLC, announced that Takeda has made a strategic investment in BioMotiv and that they have formed a partnership that will leverage the strengths of both organizations to identify and develop pioneering medical innovations. The initial investment is $25 million over five years. This investment includes exclusive rights relating to programs sourced by BioMotiv specifically in the therapeutic areas of Immunology & Inflammation and Cardio-metabolic Diseases. Launched in 2012, The Harrington Project for Discovery & Development is a $250 million national initiative, comprising the not-for-profit Harrington Discovery Institute and BioMotiv, a for-profit therapeutic accelerator. The fundamental aim is to identify, fund and rapidly advance the development of medical breakthroughs from the most innovative and respected research institutions, as well as disease foundations, throughout the USA. This initiative is unique in targeting physician-scientist discoveries and providing bench-to-bedside clinical insights into disorders where the demand for truly innovative, new medicines is paramount.
Similar Private Companies By Industry
Recent Private Companies Transactions
September 25, 2014